no reasons to fall, no reasons to rise,only waiting for real news about EPIC results
they don't reached statistical significate in P2 , results seem very close for GLYC and MSTX.
It's interesting that the 2 drugs have different mechanism , then maybe they could used in combo.
About an interim, I think that with more than half patients dosed all should be clear about effects,
By July they should be 2/3 and By September 3/4 of 388 planned, the right moment to disclose something
do you think that Tera know if Multikine work ?
Yes they know... and they haven't any interest in it and in CVM .
It's so clear ...
I read the P2 results of Rivipansel, they don't seem better than PP188, Maybe Pfizer above all is interest on Rivipansel for cancer, but in any case they pay for SCD trial.
I don't know if this is a bad news for MSTX or a good news , I only think that Mast should speed up the trial to finish in few months and give results by December. Maybe an interim on 2/3 of patinets should be even better.
GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel.
a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis (VOC) in patients hospitalized with sickle cell disease who are six years of age or older. The start of this trial triggered the second of two milestone payments from Pfizer to GlycoMimetics totaling $35 million for Phase 3 initiation. GlycoMimetics received a $15 million milestone payment from Pfizer in May 2014.
the problem is that MK doesn't work enough. It was an old hope ,maybe 20 years ago.
Ask Geert why they hasn't planned an interim result
ADXS is another story.
ADXS in few years has developped innovative drugs ,CVM in 30 year the same old drug , a "mix" of natural interleukines , some already used in cancer with poor results,.It's clear that this drug doesn't work so well as the CEO says. It is only a lure for sucker
Keytruda is a Checkpoint inhibitor , a very innovative drug. (google it)
Immunotherapy with checkpoints inhibitors is giving terrific results even against advanced cancer. Other drugs are outdated and ineffective.
Multikine is a useless drug now, CVM lost his train of innovation 20 years ago.
Bad news for CVM shareholders but good for patients
Now we know.
ARNA and MSTX have drugs in competition and Lief were in potential conflict of interest .
No a bad news , the company is running